Small molecule · Inhibitor of vascular endothelial growth factor receptor 1 (FLT1), vascular endothelial growth factor receptor 2 (KDR) and vascular endothelial growth factor receptor 3 (FLT4) · developed by Hutchmed
Surufatinib is an orally bioavailable small molecule that inhibits vascular endothelial growth factor receptors 1, 2 and 3 and fibroblast growth factor receptor 1, reducing angiogenesis and tumor cell proliferation. It is being studied in solid tumors including pancreatic, colorectal, neuroendocrine, small cell lung, gastric, and ovarian cancers, soft tissue sarcoma, and anaplastic thyroid cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06361888 | Phase 2/3 | Metastatic Pancreatic Cancer | Recruiting | HCM |
| NCT05494580 | Phase 1/2 | Ovarian Cancer | Completed | HCM |
| NCT04579757 | Phase 1/2 | Metastatic Solid Tumor | Terminated | HCM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Metastatic Pancreatic CancerAnaplastic Thyroid CancerColorectal CancerFallopian Tube CarcinosarcomaGastric CancerMetastatic Solid TumorNeuroendocrine TumorsOvarian CancerOvarian CarcinomaPlatinum-resistant Ovarian CancerPrimary Peritoneal CancerSmall Cell Lung CancerSoft Tissue Sarcoma
See HCM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HCM catalysts and pipeline →